Cara Therapeutics, Inc.
CARA
Classement en actions
#9881
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Prix de l'action
$15.96
Dernière synchronisation: 2025-04-15
Capitalisation boursière
$875.31M
Changement (1 jour)
-4.14%
Changement (1 an)
-0.19%
Pays
US
Échange Cara Therapeutics, Inc. (CARA)
Catégorie
Healthcare
Capitalisation boursière de Cara Therapeutics, Inc.(CARA)
Capitalisation boursière: $875.31M
En October 2026, Cara Therapeutics, Inc. a une capitalisation boursière de $875.31M. Cela fait de Cara Therapeutics, Inc. la 9881st entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Cara Therapeutics, Inc. du 2018 au 2026
CARA par rapport au top 5 des plus populaires stocks
| Prix pour CARA | L’actif B | La capitalisation boursière de B | Résultats | |
|---|---|---|---|---|
$3,395,620
$24.33M
|
$5.167T | +21,235,796.41% | ||
|
$3,295,559
$24.33M
|
$5.015T | +20,610,023.16% | ||
|
$2,699,916
$24.33M
|
$4.108T | +16,884,925.87% | ||
|
$2,564,211
$24.33M
|
$3.902T | +16,036,242.67% | ||
|
$1,767,428
$24.33M
|
$2.689T | +11,053,232.26% |
